These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31468659)

  • 21. The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial.
    van Steen SC; Schrieks IC; Hoekstra JB; Lincoff AM; Tardif JC; Mellbin LG; Rydén L; Grobbee DE; DeVries JH;
    Eur J Prev Cardiol; 2017 May; 24(8):858-866. PubMed ID: 28186441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite.
    Bopst M; Atzpodien EA
    Regul Toxicol Pharmacol; 2017 Jun; 86():107-116. PubMed ID: 28274810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.
    Schrieks IC; Nozza A; Stähli BE; Buse JB; Henry RR; Malmberg K; Neal B; Nicholls SJ; Rydén L; Mellbin L; Svensson A; Wedel H; Weichert A; Lincoff AM; Tardif JC; Grobbee DE; Schwartz GG
    Diabetes Care; 2018 Aug; 41(8):1792-1800. PubMed ID: 29903845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat.
    Bénardeau A; Verry P; Atzpodien EA; Funk JM; Meyer M; Mizrahi J; Winter M; Wright MB; Uhles S; Sebokova E
    Diabetes Obes Metab; 2013 Feb; 15(2):164-74. PubMed ID: 22958363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.
    Lecka-Czernik B
    IDrugs; 2010 Nov; 13(11):793-801. PubMed ID: 21046527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors.
    Dietz M; Mohr P; Kuhn B; Maerki HP; Hartman P; Ruf A; Benz J; Grether U; Wright MB
    ChemMedChem; 2012 Jun; 7(6):1101-11. PubMed ID: 22489042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.
    Deehan R; Maerz-Weiss P; Catlett NL; Steiner G; Wong B; Wright MB; Blander G; Elliston KO; Ladd W; Bobadilla M; Mizrahi J; Haefliger C; Edgar A
    PLoS One; 2012; 7(4):e35012. PubMed ID: 22514701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice.
    Boujon V; Uhlemann R; Wegner S; Wright MB; Laufs U; Endres M; Kronenberg G; Gertz K
    J Mol Med (Berl); 2019 Aug; 97(8):1127-1138. PubMed ID: 31147725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome.
    Morici N; Savonitto S; Ponticelli C; Schrieks IC; Nozza A; Cosentino F; Stähli BE; Perrone Filardi P; Schwartz GG; Mellbin L; Lincoff AM; Tardif JC; Grobbee DE
    Am J Med; 2017 Sep; 130(9):1068-1075. PubMed ID: 28344139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar.
    Grobbee EJ; de Jong VD; Schrieks IC; Tushuizen ME; Holleboom AG; Tardif JC; Lincoff AM; Schwartz GG; Castro Cabezas M; Grobbee DE
    PLoS One; 2022; 17(11):e0277706. PubMed ID: 36378671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.
    Bénardeau A; Benz J; Binggeli A; Blum D; Boehringer M; Grether U; Hilpert H; Kuhn B; Märki HP; Meyer M; Püntener K; Raab S; Ruf A; Schlatter D; Mohr P
    Bioorg Med Chem Lett; 2009 May; 19(9):2468-73. PubMed ID: 19349176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome.
    Stähli BE; Nozza A; Schrieks IC; Buse JB; Malmberg K; Mellbin L; Neal B; Nicholls SJ; Rydén L; Svensson A; Wedel H; Weichert A; Lincoff AM; Grobbee DE; Tardif JC; Schwartz GG
    J Clin Endocrinol Metab; 2018 Jul; 103(7):2522-2533. PubMed ID: 29659887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aleglitazar, a Balanced Dual PPARα and -γ Agonist, Protects the Heart Against Ischemia-Reperfusion Injury.
    Qian J; Chen H; Birnbaum Y; Nanhwan MK; Bajaj M; Ye Y
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):129-41. PubMed ID: 26861490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute coronary syndromes: Aleglitazar trial findings reported.
    Mearns BM
    Nat Rev Cardiol; 2014 Jun; 11(6):311. PubMed ID: 24736759
    [No Abstract]   [Full Text] [Related]  

  • 36. Beneficial Effects of the Peroxisome Proliferator-Activated Receptor α/γ Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension.
    Tsai HC; Li TH; Huang CC; Huang SF; Liu RS; Yang YY; Hsieh YC; Lee KC; Huang YH; Hou MC; Lin HC
    Am J Pathol; 2018 Jul; 188(7):1608-1624. PubMed ID: 29929914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
    Nissen SE; Wolski K; Topol EJ
    JAMA; 2005 Nov; 294(20):2581-6. PubMed ID: 16239637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Ojeifo O; Wiviott SD; Antman EM; Murphy SA; Udell JA; Bates ER; Mega JL; Sabatine MS; O'Donoghue ML
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1275-81. PubMed ID: 24239201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
    Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
    J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Rastogi A; Dunbar RL; Thacker HP; Bhatt J; Parmar K; Parmar DV
    Acta Diabetol; 2020 Jul; 57(7):809-818. PubMed ID: 32030508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.